Abstract | PURPOSE: To describe the demographic and clinical characteristics, including health-related quality-of-life (HRQL), in patients with psoriatic arthritis (PsA). METHODS: 287 patients from 18 Spanish centres were assessed. PsA severity was measured using the following criteria: (1) Psoriasis Area and Severity Index (PASI score 0-72, from low to high severity); (2) number of swollen and tender joints; and (3) Health Assessment Questionnaire ( HAQ score 0-3 from low to high impairment in daily activities). HRQL assessment was performed using the following criteria: (a) EuroQol-5D (EQ-5D scores 1-3, with a higher score representing a worse HRQL), Visual Analogue Scale (VAS score 0-100, with a higher score representing a better HQRL) and (b) Short Form-36 (SF-36 score 0-100, with a higher score representing a better HRQL). RESULTS: 24.7% of patients were treated with infliximab. In the two groups, 55.7% of the patients were male with a mean age of 52.40±12.53 years. The average number of swollen joints was higher in patients not receiving biological therapy than in those receiving treatment (2.98 vs. 1.54). The mean PASI score was 3.73±5.83, and there was no difference between groups. HAQ scores were higher in patients receiving infliximab than in those not receiving treatment (0.93 vs. 0.70). The mean EQ-5D scores in the two groups indicated a poorer status based on pain and inability to perform usual/daily activities. HRQL measured by VAS score mean was 60.41 ± 20.08, and there was no difference between the groups. The domains in the SF-36 suggesting poorer functioning in the two groups were the physical role (50.76 ± 43.43), physical pain (49.35 ± 25.69) and the overall physical component (37.88 ± 10.87). CONCLUSIONS: PsA is associated with an impaired HRQL characterised by physical pain and poorer functioning in daily activities.
|
Authors | Jordi Gratacós, Esteban Daudén, Juan Gómez-Reino, José Carlos Moreno, Miguel Ángel Casado, Vicente Rodríguez-Valverde |
Journal | Reumatologia clinica
(Reumatol Clin)
2014 Jan-Feb
Vol. 10
Issue 1
Pg. 25-31
ISSN: 1885-1398 [Electronic] Spain |
PMID | 24099960
(Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier España, S.L. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies, Monoclonal
- Infliximab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Arthritis, Psoriatic
(drug therapy)
- Cross-Sectional Studies
- Female
- Humans
- Infliximab
- Male
- Middle Aged
- Pain Measurement
- Quality of Life
- Severity of Illness Index
- Spain
- Surveys and Questionnaires
|